Most Popular
-
1
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
2
Medical reform committee kicks off despite boycott from doctors
-
3
10-man S. Korea lose to Indonesia to miss out on Paris Olympic football qualification
-
4
Hybe-Ador feud should have limited effect on Hybe's overall performance: analysts
-
5
DP leader says he will meet Yoon without conditions
-
6
Over 9,000 hotline calls made by stalking victims in 2023
-
7
Second Gimpo civil servant found dead, after apologizing for not finishing work
-
8
[Hello India] Hyundai Motor vows to boost 'clean mobility' in India
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050672_0.jpg&u=)
-
9
Monthly users on local streaming platforms outpace Netflix, Disney+
-
10
US will take steps for three-way engagement on nuclear deterrence with S. Korea, Japan: Campbell
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050672_0.jpg&u=)
[THE INVESTOR] Celltrion has entered the final stage to introduce its biosimilar Remsima to the US following a favorable verdict from a US federal court in a patent infringement suit with Janssen Biotech, it announced Aug. 19.
The South Korean biopharmaceutical company has commenced shipment for the replica of Janssen’s Remicade, a rheumatic arthritis and autoimmune disease treatment, to accelerate the release of the drug in the US, the largest biologics market in the world.
Celltrion and its sales partner Pfizer have been planning to launch Remsima as early as October, particularly after the US Food and Drug Administration’s approval in April.
The original drug has an estimated 12 trillion won (US$10.75 billion) annual sales volume, and the US accounts for half of the market. JP Morgan estimated that Remicade’s sales will decrease by US$1 billion in 2017 in the US market.
By Hwang You-mee (glamazon@heraldcorp.com)
The South Korean biopharmaceutical company has commenced shipment for the replica of Janssen’s Remicade, a rheumatic arthritis and autoimmune disease treatment, to accelerate the release of the drug in the US, the largest biologics market in the world.
Celltrion and its sales partner Pfizer have been planning to launch Remsima as early as October, particularly after the US Food and Drug Administration’s approval in April.
The original drug has an estimated 12 trillion won (US$10.75 billion) annual sales volume, and the US accounts for half of the market. JP Morgan estimated that Remicade’s sales will decrease by US$1 billion in 2017 in the US market.
By Hwang You-mee (glamazon@heraldcorp.com)
